| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Graft vs Host Disease | 112 | 2026 | 688 | 20.550 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 54 | 2026 | 1273 | 7.020 |
Why?
|
| Bone Marrow Transplantation | 50 | 2023 | 589 | 6.240 |
Why?
|
| T-Lymphocytes | 32 | 2024 | 1707 | 4.850 |
Why?
|
| Dendritic Cells | 20 | 2019 | 435 | 4.120 |
Why?
|
| Transplantation, Homologous | 61 | 2024 | 668 | 3.870 |
Why?
|
| Histone Deacetylase Inhibitors | 10 | 2026 | 88 | 2.780 |
Why?
|
| Gastrointestinal Microbiome | 10 | 2025 | 828 | 2.350 |
Why?
|
| Intestines | 9 | 2025 | 587 | 2.220 |
Why?
|
| Transplantation Conditioning | 17 | 2024 | 327 | 2.170 |
Why?
|
| Graft vs Leukemia Effect | 8 | 2020 | 39 | 2.080 |
Why?
|
| Mice, Inbred C57BL | 46 | 2026 | 4691 | 2.040 |
Why?
|
| Mice, Inbred BALB C | 29 | 2024 | 979 | 2.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 9 | 2026 | 501 | 2.020 |
Why?
|
| Mice | 76 | 2026 | 18160 | 1.930 |
Why?
|
| Animals | 97 | 2026 | 33660 | 1.900 |
Why?
|
| MicroRNAs | 8 | 2019 | 883 | 1.870 |
Why?
|
| Inflammation | 11 | 2025 | 1478 | 1.770 |
Why?
|
| T-Lymphocytes, Regulatory | 10 | 2016 | 239 | 1.680 |
Why?
|
| Electron Transport Complex II | 2 | 2025 | 7 | 1.640 |
Why?
|
| Hydroxamic Acids | 5 | 2017 | 60 | 1.620 |
Why?
|
| Mitochondria | 4 | 2025 | 768 | 1.610 |
Why?
|
| Immunity, Cellular | 6 | 2026 | 198 | 1.590 |
Why?
|
| Colitis | 4 | 2021 | 165 | 1.590 |
Why?
|
| Hematologic Neoplasms | 8 | 2024 | 313 | 1.580 |
Why?
|
| CD8-Positive T-Lymphocytes | 12 | 2026 | 460 | 1.550 |
Why?
|
| Fatty Acids, Volatile | 4 | 2020 | 43 | 1.440 |
Why?
|
| Cytokines | 18 | 2020 | 1332 | 1.400 |
Why?
|
| Antigen-Presenting Cells | 11 | 2014 | 123 | 1.350 |
Why?
|
| STAT3 Transcription Factor | 5 | 2017 | 226 | 1.310 |
Why?
|
| RNA, Long Noncoding | 3 | 2022 | 219 | 1.260 |
Why?
|
| Stem Cells | 2 | 2025 | 703 | 1.240 |
Why?
|
| Mice, Knockout | 21 | 2026 | 3810 | 1.230 |
Why?
|
| Leukemia, Myeloid, Acute | 6 | 2021 | 607 | 1.200 |
Why?
|
| Acute Disease | 31 | 2020 | 1153 | 1.180 |
Why?
|
| Metabolome | 3 | 2025 | 325 | 1.140 |
Why?
|
| Graft vs Tumor Effect | 3 | 2020 | 8 | 1.130 |
Why?
|
| R-SNARE Proteins | 2 | 2019 | 21 | 1.120 |
Why?
|
| Autoimmunity | 2 | 2021 | 175 | 1.080 |
Why?
|
| Interleukin-10 | 3 | 2016 | 187 | 1.060 |
Why?
|
| Isoantigens | 7 | 2018 | 23 | 1.050 |
Why?
|
| Epithelial Cells | 4 | 2024 | 905 | 1.020 |
Why?
|
| Oxidative Phosphorylation | 4 | 2025 | 141 | 1.020 |
Why?
|
| Interleukin-6 | 4 | 2015 | 410 | 1.010 |
Why?
|
| Protein Processing, Post-Translational | 3 | 2016 | 360 | 1.010 |
Why?
|
| Histocompatibility Antigens Class I | 3 | 2026 | 107 | 0.970 |
Why?
|
| Interleukin-18 | 5 | 2004 | 75 | 0.960 |
Why?
|
| Cytotoxicity, Immunologic | 4 | 2026 | 271 | 0.950 |
Why?
|
| Lymphocyte Activation | 14 | 2025 | 630 | 0.950 |
Why?
|
| Immune Tolerance | 2 | 2017 | 150 | 0.950 |
Why?
|
| Tacrolimus | 3 | 2017 | 100 | 0.910 |
Why?
|
| Hematologic Diseases | 2 | 2025 | 82 | 0.880 |
Why?
|
| alpha 1-Antitrypsin | 2 | 2018 | 81 | 0.880 |
Why?
|
| Gene Expression Regulation | 10 | 2022 | 2322 | 0.870 |
Why?
|
| CD8 Antigens | 4 | 2015 | 39 | 0.850 |
Why?
|
| T-Lymphocyte Subsets | 8 | 2014 | 194 | 0.840 |
Why?
|
| Immunosuppressive Agents | 7 | 2015 | 656 | 0.830 |
Why?
|
| Immunologic Memory | 1 | 2025 | 194 | 0.820 |
Why?
|
| Epigenesis, Genetic | 3 | 2025 | 756 | 0.810 |
Why?
|
| Antigen Presentation | 5 | 2017 | 110 | 0.790 |
Why?
|
| Humans | 94 | 2026 | 130055 | 0.770 |
Why?
|
| Endoplasmic Reticulum | 2 | 2021 | 208 | 0.770 |
Why?
|
| Cells, Cultured | 12 | 2021 | 2885 | 0.760 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 4 | 2014 | 23 | 0.760 |
Why?
|
| Colon | 3 | 2021 | 363 | 0.720 |
Why?
|
| Bacteria | 2 | 2019 | 521 | 0.710 |
Why?
|
| Vulnerable Populations | 1 | 2023 | 149 | 0.700 |
Why?
|
| Immune System Diseases | 1 | 2022 | 55 | 0.690 |
Why?
|
| Gastrointestinal Diseases | 2 | 2023 | 336 | 0.680 |
Why?
|
| Female | 69 | 2026 | 70227 | 0.670 |
Why?
|
| Disease Models, Animal | 19 | 2024 | 4639 | 0.670 |
Why?
|
| COP-Coated Vesicles | 1 | 2021 | 4 | 0.670 |
Why?
|
| Autophagy-Related Protein 5 | 1 | 2020 | 13 | 0.670 |
Why?
|
| Histone Deacetylases | 4 | 2016 | 130 | 0.660 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2024 | 290 | 0.650 |
Why?
|
| Golgi Apparatus | 1 | 2021 | 92 | 0.650 |
Why?
|
| Hematology | 1 | 2020 | 42 | 0.640 |
Why?
|
| Lipopolysaccharides | 6 | 2019 | 298 | 0.620 |
Why?
|
| Cell Differentiation | 6 | 2024 | 1906 | 0.620 |
Why?
|
| Methotrexate | 2 | 2024 | 348 | 0.610 |
Why?
|
| Hematopoietic System | 1 | 2019 | 7 | 0.610 |
Why?
|
| Mice, Inbred C3H | 6 | 2019 | 95 | 0.600 |
Why?
|
| Th2 Cells | 3 | 2011 | 188 | 0.590 |
Why?
|
| Receptors, Cell Surface | 2 | 2019 | 419 | 0.590 |
Why?
|
| Sirtuin 3 | 1 | 2018 | 31 | 0.560 |
Why?
|
| Signal Transduction | 11 | 2019 | 4645 | 0.560 |
Why?
|
| Unrelated Donors | 2 | 2018 | 72 | 0.550 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2023 | 950 | 0.540 |
Why?
|
| Histocompatibility | 3 | 2021 | 42 | 0.540 |
Why?
|
| Endothelial Cells | 2 | 2019 | 520 | 0.530 |
Why?
|
| Allografts | 11 | 2019 | 220 | 0.530 |
Why?
|
| Embryonic Development | 1 | 2019 | 200 | 0.530 |
Why?
|
| RNA, Untranslated | 1 | 2018 | 109 | 0.530 |
Why?
|
| Intestinal Mucosa | 2 | 2021 | 763 | 0.520 |
Why?
|
| Steroids | 1 | 2018 | 168 | 0.520 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2018 | 126 | 0.520 |
Why?
|
| Receptors, Interleukin-10 | 1 | 2016 | 3 | 0.510 |
Why?
|
| Myeloid Cells | 1 | 2017 | 112 | 0.490 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2020 | 499 | 0.480 |
Why?
|
| Molecular Targeted Therapy | 2 | 2020 | 383 | 0.480 |
Why?
|
| T-Lymphocytes, Cytotoxic | 5 | 2018 | 510 | 0.470 |
Why?
|
| Peer Review, Research | 1 | 2016 | 45 | 0.460 |
Why?
|
| Butyrates | 3 | 2023 | 39 | 0.460 |
Why?
|
| Transplantation Immunology | 3 | 2016 | 40 | 0.450 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2025 | 542 | 0.450 |
Why?
|
| Models, Biological | 2 | 2018 | 1375 | 0.450 |
Why?
|
| Trans-Activators | 2 | 2013 | 695 | 0.440 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2015 | 31 | 0.440 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2017 | 211 | 0.440 |
Why?
|
| Immunotherapy | 2 | 2017 | 758 | 0.430 |
Why?
|
| Dysbiosis | 3 | 2025 | 144 | 0.430 |
Why?
|
| Busulfan | 3 | 2015 | 51 | 0.420 |
Why?
|
| Boronic Acids | 1 | 2014 | 48 | 0.420 |
Why?
|
| Receptor, Notch1 | 2 | 2013 | 78 | 0.420 |
Why?
|
| CD24 Antigen | 1 | 2014 | 32 | 0.420 |
Why?
|
| Acetylation | 4 | 2017 | 191 | 0.420 |
Why?
|
| Lectins | 1 | 2014 | 50 | 0.410 |
Why?
|
| Immune System | 3 | 2022 | 99 | 0.410 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2014 | 31 | 0.410 |
Why?
|
| Pyrazines | 1 | 2014 | 79 | 0.410 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2016 | 151 | 0.410 |
Why?
|
| Carrier Proteins | 2 | 2016 | 996 | 0.410 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2014 | 57 | 0.400 |
Why?
|
| Mycophenolic Acid | 1 | 2013 | 54 | 0.400 |
Why?
|
| Ubiquitins | 1 | 2013 | 39 | 0.390 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 5 | 2019 | 992 | 0.390 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 3 | 2019 | 31 | 0.390 |
Why?
|
| Biomarkers | 12 | 2019 | 3358 | 0.390 |
Why?
|
| Hematopoiesis | 2 | 2011 | 213 | 0.380 |
Why?
|
| Leukemia | 5 | 2013 | 375 | 0.380 |
Why?
|
| Adult | 30 | 2026 | 30999 | 0.370 |
Why?
|
| Mice, Transgenic | 6 | 2021 | 2330 | 0.370 |
Why?
|
| Models, Animal | 3 | 2018 | 449 | 0.370 |
Why?
|
| H-Y Antigen | 1 | 2011 | 1 | 0.360 |
Why?
|
| Leukocyte Transfusion | 1 | 2011 | 7 | 0.360 |
Why?
|
| Glycolysis | 2 | 2025 | 173 | 0.360 |
Why?
|
| Tissue Donors | 6 | 2018 | 506 | 0.350 |
Why?
|
| Pancreatitis-Associated Proteins | 5 | 2018 | 15 | 0.350 |
Why?
|
| Basophils | 1 | 2011 | 11 | 0.350 |
Why?
|
| Adaptation, Physiological | 1 | 2013 | 258 | 0.350 |
Why?
|
| Survival Rate | 13 | 2019 | 2106 | 0.340 |
Why?
|
| Ikaros Transcription Factor | 1 | 2011 | 34 | 0.340 |
Why?
|
| Recurrence | 6 | 2021 | 1475 | 0.340 |
Why?
|
| Middle Aged | 31 | 2025 | 28303 | 0.340 |
Why?
|
| Inflammation Mediators | 3 | 2013 | 226 | 0.330 |
Why?
|
| Toll-Like Receptor 4 | 3 | 2019 | 141 | 0.330 |
Why?
|
| Immunity, Innate | 3 | 2019 | 405 | 0.330 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 5 | 2017 | 51 | 0.330 |
Why?
|
| Flow Cytometry | 4 | 2019 | 765 | 0.320 |
Why?
|
| Microbiota | 3 | 2025 | 435 | 0.320 |
Why?
|
| Cell Proliferation | 7 | 2021 | 2462 | 0.320 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2013 | 598 | 0.320 |
Why?
|
| Apoptosis | 6 | 2018 | 1826 | 0.310 |
Why?
|
| Male | 39 | 2026 | 64375 | 0.310 |
Why?
|
| Survival Analysis | 6 | 2017 | 1481 | 0.300 |
Why?
|
| Interleukin-1 Receptor-Like 1 Protein | 3 | 2018 | 22 | 0.290 |
Why?
|
| Enzyme Inhibitors | 2 | 2009 | 559 | 0.290 |
Why?
|
| Sepsis | 2 | 2011 | 494 | 0.290 |
Why?
|
| Nuclear Proteins | 1 | 2015 | 1208 | 0.290 |
Why?
|
| Cell Communication | 3 | 2021 | 188 | 0.290 |
Why?
|
| Histones | 3 | 2017 | 541 | 0.270 |
Why?
|
| Aged | 22 | 2020 | 20816 | 0.270 |
Why?
|
| Transcription, Genetic | 1 | 2013 | 1363 | 0.270 |
Why?
|
| Feces | 3 | 2024 | 718 | 0.270 |
Why?
|
| RNA, Messenger | 1 | 2013 | 2548 | 0.270 |
Why?
|
| Feasibility Studies | 2 | 2023 | 820 | 0.260 |
Why?
|
| Myeloablative Agonists | 3 | 2015 | 23 | 0.260 |
Why?
|
| Semaphorins | 1 | 2007 | 40 | 0.260 |
Why?
|
| Disease-Free Survival | 7 | 2019 | 902 | 0.260 |
Why?
|
| Interleukins | 1 | 2008 | 121 | 0.260 |
Why?
|
| Cognition | 2 | 2026 | 819 | 0.260 |
Why?
|
| Immunoglobulin G | 4 | 2014 | 781 | 0.260 |
Why?
|
| Up-Regulation | 3 | 2015 | 823 | 0.250 |
Why?
|
| Gene Expression Profiling | 4 | 2018 | 1800 | 0.250 |
Why?
|
| Antineoplastic Agents | 2 | 2014 | 1800 | 0.250 |
Why?
|
| Receptors, Tumor Necrosis Factor | 4 | 2014 | 73 | 0.250 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 2574 | 0.250 |
Why?
|
| Graft Survival | 3 | 2014 | 462 | 0.240 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2012 | 784 | 0.240 |
Why?
|
| Killer Cells, Natural | 3 | 2026 | 351 | 0.240 |
Why?
|
| Succinate Dehydrogenase | 1 | 2025 | 12 | 0.240 |
Why?
|
| Gene Expression | 4 | 2016 | 1482 | 0.230 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2018 | 137 | 0.230 |
Why?
|
| Transcription Factors | 1 | 2015 | 2400 | 0.230 |
Why?
|
| Multiple Myeloma | 2 | 2019 | 177 | 0.220 |
Why?
|
| Stomatitis | 1 | 2025 | 14 | 0.220 |
Why?
|
| Photochemotherapy | 1 | 2005 | 39 | 0.220 |
Why?
|
| Cyclopentanes | 2 | 2016 | 21 | 0.220 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2018 | 354 | 0.220 |
Why?
|
| Immunophenotyping | 2 | 2018 | 332 | 0.210 |
Why?
|
| Lymphocyte Culture Test, Mixed | 2 | 2018 | 22 | 0.210 |
Why?
|
| Mouth | 1 | 2025 | 68 | 0.210 |
Why?
|
| Bacteroides | 1 | 2024 | 36 | 0.210 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 4 | 2017 | 33 | 0.210 |
Why?
|
| Lymphocyte Depletion | 2 | 2019 | 124 | 0.210 |
Why?
|
| Membrane Glycoproteins | 2 | 2004 | 406 | 0.210 |
Why?
|
| Minor Histocompatibility Antigens | 2 | 2018 | 36 | 0.210 |
Why?
|
| Homeostasis | 2 | 2019 | 712 | 0.210 |
Why?
|
| B-Lymphocytes | 4 | 2016 | 508 | 0.200 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2005 | 163 | 0.200 |
Why?
|
| Th1 Cells | 1 | 2004 | 158 | 0.200 |
Why?
|
| Genomic Imprinting | 1 | 2024 | 122 | 0.200 |
Why?
|
| NF-kappa B | 3 | 2015 | 439 | 0.200 |
Why?
|
| Regeneration | 2 | 2024 | 226 | 0.200 |
Why?
|
| Peroxidase | 2 | 2020 | 63 | 0.200 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2023 | 33 | 0.200 |
Why?
|
| Etanercept | 5 | 2015 | 44 | 0.200 |
Why?
|
| Organ Specificity | 3 | 2017 | 394 | 0.190 |
Why?
|
| Colonic Neoplasms | 1 | 2026 | 261 | 0.190 |
Why?
|
| Mastocytoma | 1 | 2002 | 1 | 0.190 |
Why?
|
| Medically Underserved Area | 1 | 2023 | 87 | 0.190 |
Why?
|
| Chronic Disease | 6 | 2025 | 1241 | 0.190 |
Why?
|
| Photopheresis | 2 | 2015 | 5 | 0.190 |
Why?
|
| Adolescent | 20 | 2026 | 20797 | 0.180 |
Why?
|
| Quinone Reductases | 1 | 2021 | 3 | 0.180 |
Why?
|
| Hydrogen Sulfide | 1 | 2021 | 8 | 0.180 |
Why?
|
| Forkhead Transcription Factors | 3 | 2014 | 373 | 0.180 |
Why?
|
| Succinic Acid | 1 | 2021 | 13 | 0.180 |
Why?
|
| Prospective Studies | 7 | 2018 | 6401 | 0.180 |
Why?
|
| Lectins, C-Type | 2 | 2012 | 70 | 0.170 |
Why?
|
| Pyrimidines | 2 | 2016 | 454 | 0.170 |
Why?
|
| Histocompatibility Testing | 4 | 2016 | 109 | 0.170 |
Why?
|
| Protein Binding | 2 | 2016 | 1649 | 0.170 |
Why?
|
| Minority Groups | 1 | 2023 | 259 | 0.170 |
Why?
|
| Paneth Cells | 2 | 2018 | 22 | 0.170 |
Why?
|
| Organoids | 1 | 2024 | 297 | 0.170 |
Why?
|
| Immunity, Mucosal | 1 | 2021 | 95 | 0.170 |
Why?
|
| Immunoprecipitation | 2 | 2013 | 189 | 0.170 |
Why?
|
| HLA Antigens | 2 | 2016 | 225 | 0.170 |
Why?
|
| Biological Transport, Active | 1 | 2021 | 70 | 0.170 |
Why?
|
| Neutropenia | 1 | 2022 | 209 | 0.170 |
Why?
|
| Mammals | 1 | 2022 | 252 | 0.170 |
Why?
|
| Cell Line | 3 | 2019 | 2554 | 0.170 |
Why?
|
| Mice, Mutant Strains | 2 | 2011 | 354 | 0.160 |
Why?
|
| Erythropoiesis | 1 | 2020 | 39 | 0.160 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2016 | 1205 | 0.160 |
Why?
|
| Quality of Life | 3 | 2026 | 2069 | 0.160 |
Why?
|
| Spleen | 3 | 2019 | 258 | 0.160 |
Why?
|
| Histocompatibility Antigens Class II | 4 | 2010 | 71 | 0.160 |
Why?
|
| Interferon-alpha | 1 | 2021 | 238 | 0.160 |
Why?
|
| Erythropoietin | 1 | 2020 | 102 | 0.150 |
Why?
|
| Young Adult | 10 | 2026 | 9978 | 0.150 |
Why?
|
| Severity of Illness Index | 4 | 2014 | 3026 | 0.150 |
Why?
|
| Membrane Proteins | 4 | 2020 | 1589 | 0.150 |
Why?
|
| Mice, Inbred Strains | 3 | 2008 | 263 | 0.150 |
Why?
|
| Carnitine O-Palmitoyltransferase | 1 | 2019 | 26 | 0.150 |
Why?
|
| Long Interspersed Nucleotide Elements | 1 | 2019 | 38 | 0.150 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2019 | 57 | 0.150 |
Why?
|
| Maintenance Chemotherapy | 1 | 2019 | 23 | 0.150 |
Why?
|
| Antigens, Neoplasm | 2 | 2012 | 393 | 0.150 |
Why?
|
| Genome, Mitochondrial | 1 | 2019 | 26 | 0.150 |
Why?
|
| Endotoxins | 1 | 2019 | 50 | 0.140 |
Why?
|
| Glucocorticoids | 2 | 2014 | 345 | 0.140 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2018 | 14 | 0.140 |
Why?
|
| Melanoma | 1 | 2026 | 927 | 0.140 |
Why?
|
| Bone Marrow | 1 | 2020 | 317 | 0.140 |
Why?
|
| Stem Cell Transplantation | 2 | 2015 | 224 | 0.140 |
Why?
|
| Macrophages | 2 | 2020 | 659 | 0.140 |
Why?
|
| Interferon-gamma | 7 | 2015 | 542 | 0.140 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2019 | 129 | 0.140 |
Why?
|
| Interferon Regulatory Factor-7 | 1 | 2018 | 13 | 0.140 |
Why?
|
| Cell- and Tissue-Based Therapy | 2 | 2024 | 150 | 0.140 |
Why?
|
| Activating Transcription Factor 4 | 1 | 2018 | 34 | 0.140 |
Why?
|
| Lymphocytes | 1 | 2019 | 345 | 0.130 |
Why?
|
| NIH 3T3 Cells | 2 | 2019 | 91 | 0.130 |
Why?
|
| Cross-Priming | 1 | 2017 | 5 | 0.130 |
Why?
|
| Embryo, Mammalian | 1 | 2019 | 404 | 0.130 |
Why?
|
| Bone Marrow Cells | 2 | 2016 | 243 | 0.130 |
Why?
|
| Primary Cell Culture | 2 | 2018 | 106 | 0.130 |
Why?
|
| Mice, Inbred DBA | 2 | 2010 | 43 | 0.130 |
Why?
|
| Drug Resistance | 1 | 2018 | 242 | 0.130 |
Why?
|
| Physicians | 1 | 2024 | 626 | 0.130 |
Why?
|
| Administration, Intravenous | 1 | 2018 | 172 | 0.130 |
Why?
|
| Cellular Microenvironment | 1 | 2017 | 12 | 0.130 |
Why?
|
| Models, Immunological | 1 | 2017 | 35 | 0.130 |
Why?
|
| Interleukin-15 | 1 | 2018 | 104 | 0.130 |
Why?
|
| Protein Transport | 2 | 2020 | 365 | 0.130 |
Why?
|
| Neuroprotective Agents | 1 | 2018 | 157 | 0.130 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2024 | 1264 | 0.130 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2018 | 376 | 0.130 |
Why?
|
| Inflammasomes | 1 | 2018 | 153 | 0.130 |
Why?
|
| Lymphocyte Count | 2 | 2014 | 118 | 0.120 |
Why?
|
| Demography | 1 | 2017 | 236 | 0.120 |
Why?
|
| Neutrophils | 1 | 2018 | 362 | 0.120 |
Why?
|
| RNA Interference | 1 | 2018 | 491 | 0.120 |
Why?
|
| Fatty Acids | 1 | 2019 | 373 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 3 | 2010 | 977 | 0.120 |
Why?
|
| Adaptive Immunity | 1 | 2017 | 100 | 0.120 |
Why?
|
| Methylprednisolone | 2 | 2007 | 94 | 0.120 |
Why?
|
| Acute Kidney Injury | 1 | 2023 | 700 | 0.120 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2016 | 63 | 0.120 |
Why?
|
| Microarray Analysis | 1 | 2016 | 223 | 0.120 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2018 | 331 | 0.120 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2013 | 183 | 0.120 |
Why?
|
| Ubiquitination | 1 | 2016 | 175 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 1 | 2019 | 1453 | 0.120 |
Why?
|
| E2F7 Transcription Factor | 1 | 2015 | 1 | 0.110 |
Why?
|
| Immunoblotting | 1 | 2016 | 291 | 0.110 |
Why?
|
| Chemokines | 1 | 2016 | 126 | 0.110 |
Why?
|
| Transplantation, Autologous | 1 | 2016 | 253 | 0.110 |
Why?
|
| Transplant Recipients | 1 | 2017 | 230 | 0.110 |
Why?
|
| Enzyme Activation | 2 | 2013 | 576 | 0.110 |
Why?
|
| Histone Acetyltransferases | 1 | 2016 | 226 | 0.110 |
Why?
|
| Child, Preschool | 13 | 2026 | 15005 | 0.110 |
Why?
|
| Stomach Diseases | 1 | 2015 | 56 | 0.110 |
Why?
|
| Intestinal Diseases | 1 | 2015 | 67 | 0.110 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2014 | 23 | 0.110 |
Why?
|
| Vidarabine | 1 | 2015 | 91 | 0.110 |
Why?
|
| Leukocyte Common Antigens | 1 | 2014 | 84 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2019 | 565 | 0.110 |
Why?
|
| Glucose | 1 | 2019 | 851 | 0.110 |
Why?
|
| Leukemia, Experimental | 2 | 2005 | 16 | 0.110 |
Why?
|
| Haplotypes | 1 | 2016 | 517 | 0.110 |
Why?
|
| Case-Control Studies | 1 | 2021 | 3349 | 0.110 |
Why?
|
| Bortezomib | 1 | 2014 | 71 | 0.110 |
Why?
|
| Radiation | 1 | 2014 | 3 | 0.110 |
Why?
|
| Sialic Acid Binding Immunoglobulin-like Lectins | 1 | 2014 | 7 | 0.110 |
Why?
|
| Genes, Transgenic, Suicide | 1 | 2014 | 48 | 0.100 |
Why?
|
| Cyclosporine | 1 | 2015 | 132 | 0.100 |
Why?
|
| Calcineurin Inhibitors | 1 | 2014 | 25 | 0.100 |
Why?
|
| Interleukin-17 | 1 | 2015 | 125 | 0.100 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2018 | 324 | 0.100 |
Why?
|
| Acute Lung Injury | 1 | 2015 | 68 | 0.100 |
Why?
|
| Genome | 1 | 2016 | 451 | 0.100 |
Why?
|
| In Vitro Techniques | 1 | 2015 | 808 | 0.100 |
Why?
|
| Argonaute Proteins | 1 | 2013 | 29 | 0.100 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 2013 | 33 | 0.100 |
Why?
|
| DNA | 1 | 2019 | 1398 | 0.100 |
Why?
|
| Clinical Trials as Topic | 3 | 2014 | 1120 | 0.100 |
Why?
|
| Thymectomy | 2 | 2011 | 24 | 0.100 |
Why?
|
| beta-Transducin Repeat-Containing Proteins | 1 | 2013 | 6 | 0.100 |
Why?
|
| Risk Factors | 9 | 2017 | 10956 | 0.100 |
Why?
|
| I-kappa B Proteins | 1 | 2013 | 36 | 0.100 |
Why?
|
| Biomarkers, Tumor | 2 | 2012 | 1576 | 0.100 |
Why?
|
| NEDD8 Protein | 1 | 2013 | 20 | 0.100 |
Why?
|
| Lung Neoplasms | 1 | 2023 | 1547 | 0.100 |
Why?
|
| Receptor, Notch2 | 1 | 2013 | 12 | 0.100 |
Why?
|
| Radiation Tolerance | 2 | 2011 | 61 | 0.100 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2014 | 352 | 0.100 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2013 | 97 | 0.100 |
Why?
|
| Atherosclerosis | 1 | 2020 | 947 | 0.090 |
Why?
|
| Cell Cycle | 1 | 2015 | 593 | 0.090 |
Why?
|
| Hepatocyte Growth Factor | 2 | 2012 | 33 | 0.090 |
Why?
|
| Gene Knockdown Techniques | 1 | 2013 | 378 | 0.090 |
Why?
|
| Proteolysis | 1 | 2013 | 199 | 0.090 |
Why?
|
| Whole-Body Irradiation | 2 | 2012 | 61 | 0.090 |
Why?
|
| Lymphoma | 2 | 2013 | 326 | 0.090 |
Why?
|
| Child | 14 | 2026 | 26171 | 0.090 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2011 | 52 | 0.090 |
Why?
|
| Infant | 11 | 2018 | 13266 | 0.090 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2020 | 848 | 0.090 |
Why?
|
| Aging | 2 | 2014 | 1238 | 0.090 |
Why?
|
| Adenine Nucleotides | 1 | 2011 | 36 | 0.090 |
Why?
|
| Arabinonucleosides | 1 | 2011 | 32 | 0.090 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 888 | 0.090 |
Why?
|
| Patient Participation | 1 | 2014 | 252 | 0.090 |
Why?
|
| Receptors, Notch | 1 | 2013 | 197 | 0.090 |
Why?
|
| United States | 3 | 2024 | 11893 | 0.090 |
Why?
|
| CD11c Antigen | 1 | 2011 | 40 | 0.080 |
Why?
|
| Down-Regulation | 1 | 2013 | 646 | 0.080 |
Why?
|
| Repressor Proteins | 1 | 2015 | 757 | 0.080 |
Why?
|
| 3' Untranslated Regions | 1 | 2011 | 155 | 0.080 |
Why?
|
| Remission Induction | 3 | 2019 | 306 | 0.080 |
Why?
|
| Mice, 129 Strain | 1 | 2010 | 96 | 0.080 |
Why?
|
| Transplantation Chimera | 3 | 2005 | 44 | 0.080 |
Why?
|
| Elafin | 1 | 2010 | 2 | 0.080 |
Why?
|
| Cell Separation | 1 | 2010 | 220 | 0.080 |
Why?
|
| Incidence | 1 | 2017 | 3321 | 0.080 |
Why?
|
| Immunization, Passive | 1 | 2009 | 121 | 0.070 |
Why?
|
| Genetic Therapy | 1 | 2014 | 711 | 0.070 |
Why?
|
| Drugs, Investigational | 1 | 2009 | 27 | 0.070 |
Why?
|
| Autografts | 2 | 2019 | 27 | 0.070 |
Why?
|
| Radiation Chimera | 3 | 2003 | 16 | 0.070 |
Why?
|
| Skin | 2 | 2010 | 538 | 0.070 |
Why?
|
| Graft vs Host Reaction | 1 | 2008 | 12 | 0.070 |
Why?
|
| Immunologic Tests | 1 | 2008 | 18 | 0.070 |
Why?
|
| Proteins | 1 | 2013 | 1004 | 0.070 |
Why?
|
| Mice, Congenic | 1 | 2008 | 17 | 0.070 |
Why?
|
| Major Histocompatibility Complex | 1 | 2008 | 48 | 0.070 |
Why?
|
| Nerve Tissue Proteins | 1 | 2013 | 1076 | 0.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2014 | 907 | 0.070 |
Why?
|
| Interleukin-8 | 1 | 2008 | 200 | 0.070 |
Why?
|
| DNA Methylation | 1 | 2014 | 1075 | 0.070 |
Why?
|
| Neoplasms | 1 | 2022 | 2974 | 0.070 |
Why?
|
| HEK293 Cells | 2 | 2020 | 800 | 0.070 |
Why?
|
| Oxidation-Reduction | 2 | 2021 | 435 | 0.060 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2007 | 35 | 0.060 |
Why?
|
| Blotting, Western | 1 | 2009 | 1014 | 0.060 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2009 | 298 | 0.060 |
Why?
|
| Tumor Necrosis Factor-alpha | 6 | 2005 | 636 | 0.060 |
Why?
|
| Lung | 1 | 2015 | 1531 | 0.060 |
Why?
|
| Retrospective Studies | 9 | 2019 | 17538 | 0.060 |
Why?
|
| Prognosis | 5 | 2018 | 4845 | 0.060 |
Why?
|
| Pore Forming Cytotoxic Proteins | 2 | 2004 | 17 | 0.060 |
Why?
|
| Perforin | 2 | 2004 | 24 | 0.060 |
Why?
|
| Antigens, CD | 1 | 2008 | 409 | 0.060 |
Why?
|
| RNA, Small Interfering | 1 | 2008 | 662 | 0.060 |
Why?
|
| Phenotype | 2 | 2013 | 4456 | 0.060 |
Why?
|
| Diagnostic Imaging | 1 | 2008 | 304 | 0.060 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2007 | 688 | 0.060 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2005 | 31 | 0.060 |
Why?
|
| Bacteroides thetaiotaomicron | 1 | 2024 | 8 | 0.050 |
Why?
|
| Receptors, Interleukin-18 | 1 | 2004 | 1 | 0.050 |
Why?
|
| Interleukin-18 Receptor alpha Subunit | 1 | 2004 | 2 | 0.050 |
Why?
|
| Receptors, Interleukin | 1 | 2004 | 36 | 0.050 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2005 | 215 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2013 | 3677 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2026 | 5164 | 0.050 |
Why?
|
| Receptors, Chemokine | 1 | 2003 | 47 | 0.050 |
Why?
|
| Ontario | 1 | 2023 | 84 | 0.050 |
Why?
|
| Methylation | 2 | 2014 | 198 | 0.050 |
Why?
|
| Clonal Deletion | 1 | 2003 | 3 | 0.050 |
Why?
|
| Advisory Committees | 1 | 2024 | 148 | 0.050 |
Why?
|
| Liver | 3 | 2012 | 1783 | 0.050 |
Why?
|
| Cell Line, Tumor | 2 | 2021 | 3713 | 0.050 |
Why?
|
| H-2 Antigens | 1 | 2002 | 11 | 0.050 |
Why?
|
| Verrucomicrobia | 1 | 2022 | 18 | 0.050 |
Why?
|
| Propionates | 1 | 2022 | 31 | 0.050 |
Why?
|
| Thymus Gland | 1 | 2003 | 104 | 0.050 |
Why?
|
| Mucus | 1 | 2022 | 37 | 0.050 |
Why?
|
| STAT6 Transcription Factor | 1 | 2002 | 34 | 0.050 |
Why?
|
| Mucins | 1 | 2022 | 71 | 0.050 |
Why?
|
| Career Choice | 1 | 2024 | 165 | 0.050 |
Why?
|
| Drug Therapy, Combination | 3 | 2015 | 1165 | 0.050 |
Why?
|
| T-Box Domain Proteins | 2 | 2013 | 123 | 0.050 |
Why?
|
| Neoplasm, Residual | 1 | 2002 | 132 | 0.040 |
Why?
|
| Neoplasm Transplantation | 1 | 2002 | 358 | 0.040 |
Why?
|
| Electron Transport Complex IV | 1 | 2021 | 42 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2023 | 241 | 0.040 |
Why?
|
| Bile Acids and Salts | 1 | 2024 | 260 | 0.040 |
Why?
|
| Mutation | 1 | 2015 | 6064 | 0.040 |
Why?
|
| Dextran Sulfate | 1 | 2021 | 48 | 0.040 |
Why?
|
| Algorithms | 2 | 2019 | 1662 | 0.040 |
Why?
|
| Epithelium | 1 | 2002 | 334 | 0.040 |
Why?
|
| Serum Amyloid A Protein | 1 | 2020 | 23 | 0.040 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2021 | 136 | 0.040 |
Why?
|
| Autoimmune Diseases | 1 | 2003 | 260 | 0.040 |
Why?
|
| Gene Knockout Techniques | 1 | 2020 | 131 | 0.040 |
Why?
|
| Time Factors | 3 | 2019 | 6165 | 0.040 |
Why?
|
| Adjuvants, Immunologic | 1 | 2002 | 391 | 0.040 |
Why?
|
| Receptors, Interleukin-15 | 1 | 2019 | 3 | 0.040 |
Why?
|
| Gastrointestinal Tract | 2 | 2012 | 209 | 0.040 |
Why?
|
| Infant, Newborn | 4 | 2017 | 8547 | 0.040 |
Why?
|
| Muromegalovirus | 1 | 2019 | 12 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2024 | 791 | 0.040 |
Why?
|
| Nephrectomy | 1 | 2020 | 156 | 0.040 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2019 | 25 | 0.040 |
Why?
|
| Body Temperature | 1 | 2019 | 126 | 0.040 |
Why?
|
| Probability | 1 | 2019 | 305 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2002 | 1319 | 0.040 |
Why?
|
| Leukocyte Elastase | 1 | 2018 | 20 | 0.040 |
Why?
|
| Treatment Outcome | 5 | 2018 | 12821 | 0.040 |
Why?
|
| Tandem Repeat Sequences | 1 | 2018 | 37 | 0.030 |
Why?
|
| CRISPR-Cas Systems | 1 | 2020 | 316 | 0.030 |
Why?
|
| Metabolomics | 1 | 2021 | 500 | 0.030 |
Why?
|
| Escherichia coli Infections | 1 | 2018 | 194 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 1 | 2019 | 449 | 0.030 |
Why?
|
| Cellular Reprogramming | 1 | 2018 | 127 | 0.030 |
Why?
|
| Cell Survival | 1 | 2018 | 828 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2004 | 882 | 0.030 |
Why?
|
| Diet | 1 | 2022 | 1103 | 0.030 |
Why?
|
| Michigan | 1 | 2015 | 47 | 0.030 |
Why?
|
| Salvage Therapy | 2 | 2009 | 174 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2024 | 3780 | 0.030 |
Why?
|
| Hospitals, Teaching | 1 | 2015 | 109 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2011 | 2290 | 0.030 |
Why?
|
| Th17 Cells | 1 | 2015 | 97 | 0.030 |
Why?
|
| Bcl-2-Like Protein 11 | 1 | 2013 | 13 | 0.030 |
Why?
|
| STAT4 Transcription Factor | 1 | 2013 | 11 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 4035 | 0.030 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2013 | 69 | 0.020 |
Why?
|
| Dibenzazepines | 1 | 2013 | 3 | 0.020 |
Why?
|
| Focus Groups | 1 | 2014 | 239 | 0.020 |
Why?
|
| Escherichia coli | 1 | 2018 | 985 | 0.020 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2013 | 58 | 0.020 |
Why?
|
| Adoptive Transfer | 2 | 2005 | 235 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2013 | 157 | 0.020 |
Why?
|
| Epigenomics | 1 | 2014 | 181 | 0.020 |
Why?
|
| Th1-Th2 Balance | 1 | 2012 | 8 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 2013 | 235 | 0.020 |
Why?
|
| Interleukin-1 | 2 | 2003 | 130 | 0.020 |
Why?
|
| Keratin-18 | 1 | 2012 | 9 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 175 | 0.020 |
Why?
|
| Antibodies | 1 | 2013 | 316 | 0.020 |
Why?
|
| Calcium-Binding Proteins | 1 | 2013 | 322 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2013 | 287 | 0.020 |
Why?
|
| Informed Consent | 1 | 2014 | 350 | 0.020 |
Why?
|
| Syndrome | 1 | 2014 | 1157 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2012 | 303 | 0.020 |
Why?
|
| Diarrhea | 1 | 2013 | 299 | 0.020 |
Why?
|
| Mitochondrial Proton-Translocating ATPases | 1 | 2011 | 27 | 0.020 |
Why?
|
| Lactates | 1 | 2011 | 81 | 0.020 |
Why?
|
| Genomics | 1 | 2019 | 1615 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 723 | 0.020 |
Why?
|
| Benzodiazepines | 1 | 2011 | 105 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 2008 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2013 | 583 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 2011 | 295 | 0.020 |
Why?
|
| ROC Curve | 1 | 2012 | 609 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2013 | 613 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 1374 | 0.020 |
Why?
|
| Patient Care Planning | 1 | 2009 | 124 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2011 | 521 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2011 | 2392 | 0.020 |
Why?
|
| Forecasting | 1 | 2009 | 349 | 0.020 |
Why?
|
| Proteomics | 1 | 2011 | 614 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2011 | 3464 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2009 | 776 | 0.010 |
Why?
|
| CD40 Ligand | 1 | 2005 | 65 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2014 | 5033 | 0.010 |
Why?
|
| Fas Ligand Protein | 1 | 2004 | 33 | 0.010 |
Why?
|
| Lymphocyte Transfusion | 1 | 2004 | 55 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2005 | 308 | 0.010 |
Why?
|
| Scleroderma, Diffuse | 1 | 2003 | 4 | 0.010 |
Why?
|
| Receptors, CXCR3 | 1 | 2003 | 23 | 0.010 |
Why?
|
| Bacteremia | 1 | 2008 | 433 | 0.010 |
Why?
|
| Xerophthalmia | 1 | 2003 | 8 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2003 | 60 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2004 | 271 | 0.010 |
Why?
|
| Antigens, CD20 | 1 | 2003 | 44 | 0.010 |
Why?
|
| Transplantation, Isogeneic | 1 | 2003 | 14 | 0.010 |
Why?
|
| Self Tolerance | 1 | 2003 | 4 | 0.010 |
Why?
|
| Expressed Sequence Tags | 1 | 2003 | 76 | 0.010 |
Why?
|
| Acute-Phase Proteins | 1 | 2003 | 45 | 0.010 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2003 | 60 | 0.010 |
Why?
|
| Viscera | 1 | 2003 | 56 | 0.010 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2003 | 125 | 0.010 |
Why?
|
| Rituximab | 1 | 2003 | 171 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2009 | 1325 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 2002 | 229 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2005 | 1439 | 0.010 |
Why?
|
| Cell Division | 1 | 2002 | 718 | 0.010 |
Why?
|
| Intestine, Small | 1 | 2002 | 291 | 0.010 |
Why?
|
| Cell Movement | 1 | 2003 | 873 | 0.010 |
Why?
|